Tango details Phase 3 plans for pancreatic cancer combo, holds $977.5 millionNov 16Regulatory decisionKura Oncology, Inc.Summit TherapeuticsUpdated
Erasca reports Q3 2026 results, Fast Track status for ERAS-0015 in pancreatic cancerNov 12Quarterly updateERAS-0015Erasca, Inc.
Tango registers Phase 1/2 trial pairing vopimetostat with Erasca's ERAS-0015Oct 27Trial updateERAS-0015Erasca, Inc.
Tango reports Phase 1/2 pancreatic cancer data, eyes Phase 3 as it posts Q2 2026 resultsAug 11Quarterly updateTango Therapeutics, Inc.
Erasca updates ERAS-0015 data, plans registration-enabling trials, reports Q2 2026 resultsAug 11Quarterly updateERAS-0015Erasca, Inc.